SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending after releasing positive Phase 3 trial results for their DMD treatment, showing statistically significant improvement in both skeletal and cardiac function. The community is buzzing about the potential for FDA approval and a possible buyout by a major pharmaceutical company, with many expressing excitement about the implications for treating this rare disease. Short sellers are feeling the squeeze, as the stock experiences high volatility and a surge in trading volume.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

PLRZ is trending due to positive preclinical data for its intranasal naloxone hydrogel, with the community noting its potential as a multi-day runner. Community members are actively discussing price targets and potential short squeezes, drawing comparisons to other low-float Israeli stocks that have recently experienced significant gains. However, some are expressing caution due to the company's history of reverse splits and dilution, as well as an upcoming clinical trial not expected to start until 2026.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

UP Fintech Holding (TIGR) is trending following a strong earnings report, with revenue and net income seeing significant year-over-year growth. Community members are impressed by the results, drawing comparisons to other brokerage platforms and anticipating a potential surge in stock price. Despite positive financials, some express concerns about the company's association with Chinese stocks and the lack of an earnings date, leading to volatility.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending as the robotics sector gains attention, fueled by reports of potential government support and media coverage. Community discussions revolve around the stock's overnight price action, high short interest creating squeeze potential, and comparing SERV to other robotics plays like RR and IRBT. Some traders are citing the recent DoorDash partnership as a key catalyst for future growth, while others express concerns about recent price volatility.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to concerns about AI sales performance following a report of lowered sales quotas, which the company disputes; this has sparked debate about the strength of its AI offerings and competition from Google's Gemini. Community discussion includes frustration over the stock's price action relative to peers and broader market indices, with some viewing the dip as a buying opportunity while others express skepticism about the company's AI strategy and overall valuation. Some traders point out that a correction back to the 450 or even 300 levels may occur before eoy.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

$PLCE is gaining attention due to unusual options activity and speculation about an upcoming earnings surprise, with community members actively discussing potential short squeezes and the impact of institutional ownership. The stock's low market cap relative to its revenue and high short interest are fueling optimism for a significant price increase. Some traders point to the company's turnaround efforts and potential for increased profitability as bullish signals.

Macy's, Inc. engages in the retail of apparel, accessories, cosmetics, home furnishings, and other consumer goods. The firm's brands include Macy's, Bloomingdale's, and Bluemercury. It offers men's, women's, and children's apparel, women's accessories, intimate apparel, shoes, cosmetics, fragrances, as well as home and miscellaneous products. The company was founded by Rowland H. Macy in 1858 and is headquartered in New York, NY.

Macy`s Inc

Macy's Inc

Macy's is trending amid discussions about a potential turnaround, real estate value, and speculation around a possible buyout offer. Community members are analyzing recent earnings, comparable sales, and full-year outlook, while also debating its long-term potential and current valuation relative to its assets. Tariffs, consumer spending, and the impact of strategic initiatives are also being considered.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Recent reports suggest Netflix is vying for Warner Bros. Discovery assets, sparking community discussion around potential synergies and regulatory hurdles. The community is weighing the implications of Netflix potentially acquiring the studio and streaming service, including debates on content libraries and market dominance. Amidst these acquisition talks, there are also discussions on the stock's recent performance and future price movement, with some traders expressing bearish sentiments.

Veritone, Inc. engages in the provision of artificial intelligence (AI) computing solutions to media and entertainment, government, and legal and compliance industries. It operates through the following segments: Advertising, aiWARE SaaS Solutions, and aiWARE Content Licensing and Media Services. The Advertising segment places advertisements for clients, primarily with radio broadcasters, podcasters and digital media producers. The aiWARE SaaS Solutions segment offers solutions through a combination of its direct sales force and indirect channel partners, such as value-added resellers (VARs), distributors, system integrators, managed services providers, and referral partners. The aiWARE Content Licensing and Media Services segment sells and markets activities relating to its digital content licensing services business through its direct sales force. The company was founded by Chad Edward Steelberg and Ryan S. Steelberg on June 13, 2014 and is headquartered in Irvine, CA.

Veritone Inc

Veritone ($VERI) is trending as discussions focus on its AI-powered solutions and recent UK subsidiary pre-qualification for policing services, potentially positioning it for future contracts. Some investors highlight the company's undervaluation and potential for growth in the AI sector, while others analyze chart patterns and trading strategies. Community members are closely watching for potential contract announcements and strategic partnerships.

Bullish engages in the management of a digital asset platform. It also offers market infrastructure and information services. The company was founded by Brendan Francis Blumer in 2020 and is headquartered in George Town, Cayman Islands.

Bullish

$BLSH is trending as the crypto sector shows signs of a rebound, with some community members anticipating a breakout. Discussions include potential price targets, options activity, and speculation around institutional interest and partnerships. Some traders highlight the company's correlation to Bitcoin's performance, while others discuss its valuation and potential for growth in the digital asset space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH PR Newswire NASHVILLE, Tenn., Nov. 4, 2025 NASHVILLE, Tenn., Nov...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE PR Newswire NASHVILLE, Tenn., Oct...

CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC. CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn., Feb. 25, 2025 NASHVILLE, Tenn...

VIBATIV RECEIVES MARKETING APPROVAL IN CHINA

VIBATIV RECEIVES MARKETING APPROVAL IN CHINA VIBATIV RECEIVES MARKETING APPROVAL IN CHINA PR Newswire NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025 Vibativ is a life-saving antibiotic for pneumonia...

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease Cumberland Pharmaceuticals Announces Breakthrough Results from...

Shares of Cumberland Pharmaceuticals (CPIX) doubled on Tuesday morning, reaching levels not seen since March 2023, following FDA approval of a new dosing regimen for its liver drug, Acetadote.Acetadote, an intravenous formulation of N-acetylcysteine, helps prevent or mitigate liver injury caused by toxic acetaminophen ingestion.&nbsp;The newly approved regimen combines the first two standard doses into a single, slower infusion, simplifying administration and improving patient outcomes, according to experts.Rick Dart, MD, PhD, Director at the Rocky Mountain Poison and Drug Center, said: "By streamlining the administration of NAC, we can improve patient outcomes and reduce the risk of adverse events. This simplified dosing regimen is a valuable tool for health care providers in managing this potentially life-threatening condition."<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CPIX_sentiment_and_message_volume_Dec_10_64a13aec8e.png" alt="CPIX sentiment and message volume Dec 10.png" width="1318" height="324"><figcaption>CPIX sentiment and message volume Dec 10 as of 10:15 am ET | Source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for Cumberland shot up into ‘extremely bullish’ territory amid a surge in message volume.One user called the latest development “too much big news” to keep the stock between $5-$10 for long.<stembedurl>https://stocktwits.com/cjstocksup/message/595845075</stembedurl>Cumberland has attracted significant retail attention on Stocktwits, with watchlist growth of over 7% and message activity surging by 9,000% in the past year.In addition to Acetadote developments, Cumberland is advancing several Phase II clinical programs evaluating ifetroban, a drug candidate targeting conditions like cardiomyopathy associated with Duchenne Muscular Dystrophy, systemic sclerosis, and idiopathic pulmonary fibrosis.<a href="https://stocktwits.com/symbol/CPIX">Cumberland shares</a> are up nearly 26% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Cumberland Pharma Stock Hits 16-Month High After FDA Approves Liver Drug Regimen: Retail’s Thrilled

The newly approved regimen combines the first two standard doses into a single, slower infusion, simplifying administration and improving patient outcomes, according to experts.

Equity

FDA APPROVES ACETADOTE sNDA

FDA APPROVES ACETADOTE sNDA FDA APPROVES ACETADOTE sNDA PR Newswire NASHVILLE, Tenn., Dec. 9, 2024 - New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire...

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update PR Newswire...

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND...

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

CPIX
Cumberland Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CPIX News

CPIXCumberland Pharmaceuticals Inc.